At Vyriad, we are developing the next generation of targeted genetic therapies by engineering viruses, viral vectors and viral envelope glycoproteins to deliver genes directly to targeted cells. This targeting technology facilitates oncolytic virotherapy, in vivo gene therapies and gene editing applications. We are testing our oncolytic viruses as monotherapies and in combination with immuno-oncology drugs. Phase 1-2 Clinical Studies are currently active in: Non-small cell lung cancer Squamous cell carcinoma of the head and neck Metastatic colorectal cancer Breast cancer Bladder cancer Other cancer types Vyriad has clinical research collaboration agreements with Regeneron, Mayo Clinic, and other leading research and medical Read more